Blenoxane
(Bleomycin)ApprovedSmall molecule
Bristol-Myers SquibbBleomycin is a chemotherapy drug used to treat certain cancers, including testicular cancer, lymphoma, and squamous cell cancers. It works by damaging cancer cell DNA to stop them from growing.[2] Blenoxane is currently approved and in use across 18 indications[4].[1]
Blenoxane is one of 264 small molecule programs targeting Metastasis. It is currently in Approved.
18
Indications
64
Total Trials
19
Active Trials
263
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma17 trials
Show 14 more trials
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00369681·51 enrolled
Germ Cell Tumor4 trials
Hodgkin's Disease3 trials
Plantar Wart3 trials
Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts
Not yet recruiting·—·N/A·NCT07041749·60 enrolled
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
Unknown status·—·Phase 4·NCT03477448·40 enrolled
A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Approved·NCT07197541·200 enrolled
27 more indications
Chemotherapy2 trials
Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
Withdrawn·—·Phase 2·NCT00918593·98 enrolled
Lymphatic Malformation2 trials
Classic Hodgkin Lymphoma2 trials
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled
Venous malformation2 trials
Hodgkin Lymphoma2 trials
Brain Metastases1 trial
Electrochemotherapy as a Palliative Treatment for Brain Metastases
Terminated·—·Phase 1·NCT01322100·1 enrolled
Cancer1 trial
Diffuse Large B-Cell Lymphoma1 trial
Hodgkins lymphoma1 trial
Vulvar Cancer1 trial
Brentuximab Vedotin1 trial
Glioblastoma Multiforme1 trial
Metastasis1 trial
Germ Cell Tumors1 trial
Vascular Malformations1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
BLENOXANE
NDA NDA050443
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Blenoxane drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bleomycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company